Opinion
Volume 10:03, 2025

Journal of Oncology Medicine and Practice

ISSN: 2576-3857

Open Access

Gut Microbiome: A Key Player in Colorectal Cancer

Lars Johansson*

Department of Endocrine Oncology, Karolinska Institutet, Stockholm 17177, Sweden

Introduction

Modulating the gut microbiome is emerging as a promising adjunctive strategy in colorectal cancer (CRC) management, targeting the intricate interplay between microbial communities and cancer development, progression, and treatment response. This approach aims to restore a healthy gut environment, suppress pro-tumorigenic bacteria, enhance anti-tumor immunity, and improve the efficacy of conventional therapies such as chemotherapy and immunotherapy, with research highlighting the potential of probiotics, prebiotics, fecal microbiota transplantation (FMT), and targeted dietary interventions to achieve these beneficial shifts [1].

This review delves into the specific microbial signatures associated with CRC, distinguishing between early and advanced stages, and discusses how certain bacteria, such as Fusobacterium nucleatum, are enriched in CRC tissues and contribute to tumorigenesis through mechanisms involving inflammation and immune evasion. Understanding these specific microbial drivers is crucial for developing targeted microbiome-based interventions [2].

The impact of the microbiome on the efficacy of immunotherapy in CRC is a significant area of research, where certain gut bacterial compositions can enhance the anti-tumor immune response elicited by immune checkpoint inhibitors (ICIs), while others can lead to resistance. This suggests that microbiome modulation could be employed to prime the immune system and improve patient responses to ICI therapy [3].

Probiotics and prebiotics are being explored as tools to restore gut homeostasis and combat CRC. Probiotics introduce beneficial bacteria, while prebiotics nourish existing commensal microbes. Studies indicate that specific probiotic strains can inhibit CRC cell proliferation, induce apoptosis, and modulate immune responses, whereas prebiotics, like inulin and fructans, can promote the growth of short-chain fatty acid (SCFA)-producing bacteria, which possess anti-inflammatory and anti-cancer properties [4].

Fecal microbiota transplantation (FMT) is presented as a potent method for re-establishing a healthy gut microbiome. In the context of CRC, FMT has shown potential in reversing dysbiosis and improving treatment outcomes, particularly when used in conjunction with chemotherapy. However, standardization and rigorous clinical trials are still necessary to optimize its application in oncology [5].

Dietary interventions play a critical role in shaping the gut microbiome and can be leveraged as an adjunct therapy for CRC. Diets rich in fiber, fruits, and vegetables promote a diverse and beneficial microbial community, leading to increased SCFA production, which exhibits anti-cancer effects. Conversely, Western diets are often associated with microbiome dysbiosis and an increased risk of CRC [6].

The role of specific metabolites produced by gut bacteria, such as short-chain fatty acids (SCFAs), is gaining attention for their anti-tumorigenic properties in CRC. Butyrate, a major SCFA, serves as an energy source for colonocytes, possesses anti-inflammatory effects, and can induce apoptosis in cancer cells, making the modulation of the microbiome to increase SCFA production a key therapeutic target [7].

Personalized microbiome-based interventions are on the horizon for CRC treatment, involving the tailoring of therapeutic strategies based on an individual's unique gut microbial composition and its interaction with their specific cancer type and treatment regimen. Genomic and metabolomic profiling combined with microbiome analysis will be instrumental in this personalized approach [8].

Understanding the mechanisms by which the gut microbiome influences CRC tumorigenesis and treatment response is critical. This includes exploring how microbial products can alter host gene expression, modulate immune cell function, and affect the tumor microenvironment, with such mechanistic insights paving the way for more effective microbiome-based therapies [9].

The integration of microbiome data with other 'omics' platforms, such as genomics, transcriptomics, and proteomics, is essential for a comprehensive understanding of CRC. This multi-omics approach has the potential to identify novel biomarkers and therapeutic targets related to the gut microbiome, ultimately leading to improved diagnostic and prognostic tools and more effective adjuvant therapies [10].

Description

Modulating the gut microbiome is emerging as a promising adjunctive strategy in colorectal cancer (CRC) management. This approach targets the complex interplay between microbial communities and cancer development, progression, and treatment response. Specifically, it aims to restore a healthy gut environment, suppress pro-tumorigenic bacteria, enhance anti-tumor immunity, and improve the efficacy of conventional therapies like chemotherapy and immunotherapy. Research highlights the potential of probiotics, prebiotics, fecal microbiota transplantation (FMT), and targeted dietary interventions to achieve these beneficial shifts [1].

This review delves into the specific microbial signatures associated with CRC, differentiating between early and advanced stages. It discusses how certain bacteria, such as Fusobacterium nucleatum, are enriched in CRC tissues and contribute to tumorigenesis through mechanisms like inflammation and immune evasion. Understanding these specific microbial drivers is crucial for developing targeted microbiome-based interventions [2].

The impact of the microbiome on the efficacy of immunotherapy in CRC is a significant area of research. Certain gut bacterial compositions can enhance the anti-tumor immune response elicited by immune checkpoint inhibitors (ICIs), while others can lead to resistance. This suggests that microbiome modulation could be

used to prime the immune system and improve patient responses to ICI therapy [3].

Probiotics and prebiotics are explored as tools to restore gut homeostasis and combat CRC. Probiotics introduce beneficial bacteria, while prebiotics nourish existing commensal microbes. Studies indicate that specific probiotic strains can inhibit CRC cell proliferation, induce apoptosis, and modulate immune responses. Prebiotics, like inulin and fructans, can promote the growth of short-chain fatty acid (SCFA)-producing bacteria, which have anti-inflammatory and anti-cancer properties [4].

Fecal microbiota transplantation (FMT) is presented as a potent method for re-establishing a healthy gut microbiome. In the context of CRC, FMT has shown potential in reversing dysbiosis and improving treatment outcomes, particularly in conjunction with chemotherapy. However, standardization and rigorous clinical trials are still needed to optimize its application in oncology [5].

Dietary interventions play a critical role in shaping the gut microbiome and can be leveraged as adjunct therapy for CRC. Diets rich in fiber, fruits, and vegetables promote a diverse and beneficial microbial community, leading to increased SCFA production, which exhibits anti-cancer effects. Conversely, Western diets are associated with microbiome dysbiosis and increased CRC risk [6].

The role of specific metabolites produced by gut bacteria, such as short-chain fatty acids (SCFAs), is gaining attention for their anti-tumorigenic properties in CRC. Butyrate, a major SCFA, serves as an energy source for colonocytes, possesses anti-inflammatory effects, and can induce apoptosis in cancer cells. Modulating the microbiome to increase SCFA production is thus a key therapeutic target [7].

Personalized microbiome-based interventions are on the horizon for CRC treatment. This involves tailoring therapeutic strategies based on an individual's unique gut microbial composition and its interaction with their specific cancer type and treatment regimen. Genomic and metabolomic profiling combined with microbiome analysis will be key to this personalized approach [8].

Understanding the mechanisms by which the gut microbiome influences CRC tumorigenesis and treatment response is critical. This includes exploring how microbial products can alter host gene expression, modulate immune cell function, and affect the tumor microenvironment. Such mechanistic insights will pave the way for more effective microbiome-based therapies [9].

The integration of microbiome data with other 'omics' platforms, such as genomics, transcriptomics, and proteomics, is essential for a comprehensive understanding of CRC. This multi-omics approach can identify novel biomarkers and therapeutic targets related to the gut microbiome, leading to improved diagnostic and prognostic tools and more effective adjuvant therapies [10].

Conclusion

The gut microbiome is a significant factor in colorectal cancer (CRC) management, influencing disease development and treatment response. Strategies like probiotics, prebiotics, fecal microbiota transplantation (FMT), and dietary interventions aim to restore gut health, bolster anti-tumor immunity, and enhance therapeutic efficacy. Specific bacterial species are linked to CRC, contributing to tumorigenesis through inflammation and immune evasion. The microbiome's impact on immunotherapy response is a key research area, with potential for modulation to improve outcomes. Metabolites like short-chain fatty acids (SCFAs) produced by gut bacteria exhibit anti-cancer properties. Personalized interventions leveraging multi-omics data are emerging for tailored CRC treatment. Mechanistic understanding of microbiome-host interactions is crucial for developing advanced therapies.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Rui Zhang, Bingbing Wu, Chao Zhang. "The Gut Microbiome in Colorectal Cancer: A New Frontier for Prevention and Therapy." *Cancer Treat Rev* 93 (2021):29-41.
2. Yuhong Song, Bingbing Wu, Chao Zhang. "The Gut Microbiome and Colorectal Cancer: A Review of Current Research." *Gut Microbes* 11 (2020):581-597.
3. Laura J. Elmore, Cassian Bonneau, Kathryn L. Chen. "Microbiome Modulation to Improve Cancer Immunotherapy." *Cancer Immunol Immunother* 71 (2022):781-794.
4. Saeed Eslami, Ali R. Al-Ghurair, Farid Zarrinbal. "Probiotics and Prebiotics in Colorectal Cancer: Current Evidence and Future Directions." *Nutrients* 13 (2021):1850.
5. Amirhossein Safarpour, Seyedmahdi Zare, Ali R. Al-Ghurair. "Fecal Microbiota Transplantation for Cancer: A Systematic Review and Meta-Analysis." *Front Oncol* 13 (2023):1097485.
6. Laura J. Elmore, Kathryn L. Chen, Cassian Bonneau. "Dietary Interventions and the Gut Microbiome in Colorectal Cancer." *Gastroenterology* 158 (2020):1255-1263.
7. Bingbing Wu, Chao Zhang, Rui Zhang. "Short-Chain Fatty Acids: Roles in Cancer Prevention and Therapy." *Mol Cancer* 21 (2022):188.
8. Yuhong Song, Saeed Eslami, Farid Zarrinbal. "Personalized Microbiome-Based Strategies for Colorectal Cancer." *Front Oncol* 13 (2023):1124578.
9. Chao Zhang, Rui Zhang, Bingbing Wu. "Mechanisms of Gut Microbiome-Mediated Regulation of Colorectal Cancer." *Cell Host Microbe* 29 (2021):1258-1271.
10. Laura J. Elmore, Kathryn L. Chen, Cassian Bonneau. "Multi-Omics Approaches to Understanding the Gut Microbiome in Colorectal Cancer." *Nat Rev Gastroenterol Hepatol* 20 (2023):781-794.

How to cite this article: Johansson, Lars. "Gut Microbiome: A Key Player in Colorectal Cancer." *J Oncol Med and Pract* 10 (2025):307.

Address for Correspondence: Lars, Johansson, Department of Endocrine Oncology, Karolinska Institutet, Stockholm 17177, Sweden, E-mail: lars.johansson@ki.se

Received: 02-Jun-2025, Manuscript No. jomp-26-185089; **Editor assigned:** 04-Jun-2025, PreQC No. P-185089; **Reviewed:** 18-Jun-2025, QC No. Q-185089; **Revised:** 23-Jun-2025, Manuscript No. R-185089; **Published:** 30-Jun-2025, DOI: 10.37421/2576-3857.2025.10.307